CoChat

Potential biomarkers to follow the progression and treatment response of Huntington’s disease

Open access
Disatnik, Marie-Hélène, Joshi, Amit U., Saw, Nay L., Shamloo, Mehrdad, Leavitt, Blair R., Qi, Xin, Mochly-Rosen, Daria · 2016 · Journal of Experimental Medicine

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Abstract

Huntington’s disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the brain, making it difficult to design short and effective proof of concept clinical trials to assess treatment benefit. In this study, we focus on identifying peripheral biomarkers that correlate with the progression of the disease and treatment benefit. We recently developed an inhibitor of pathological mitochondrial fragmentation, P110, to inhibit neurotoxicity in HD. Changes in levels of mitochondrial DNA (mtDNA) and inflammation markers in plasma, a product of DNA oxidation in urine, mutant huntingtin aggregates, and 4-hydroxynonenal adducts in muscle and skin tissues were all noted in HD R6/2 mice relative to wild-type mice. Importantly, P110 treatment effectively reduced the levels of these biomarkers. Finally, abnormal levels of mtDNA were also found in plasma of HD patients relative to control subjects. Therefore, we identified several potential peripheral biomarkers as candidates to assess HD progression and the benefit of intervention for future clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20160776

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Analysis of mtDNA content in brain and plasma. (A) DNA synthetized from mouse brain tissue was used in real-time PCR with mtND2 primers targeting mouse mtDNA (n = 4 mice per group). (B) mtND2 DNA content in plasma samples from mouse blood collected at the age of 13 wk were assayed by real-time PCR (n = 10 WT and n = 8 R6/2 Tg mice). Housekeeping nuclear gene, GAPDH, was used for normalization. (C) Change in mtND2 levels over time in mice. Mouse plasma samples from WT and R6/2 mice were collected every 2 wk, and mtND2 levels were determined using real-time PCR. mtND2 levels decreased over time in R6/2 mice as compared with WT mice (n = 10 WT; n = 10 R6/2 [5–11-wk-old mice]; n = 9 [13-wk-old mice]). The data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0006; **, P = 0.0055; ***, P = 0.00017 versus WT 5 wk; #, P = 0.00085 versus WT 7 wk; ##, P = 0.004 versus WT 13 wk (unpaired Student’s t test and one-way ANOVA).
Figure 1. Analysis of mtDNA content in brain and plasma. (A) DNA synthetized from mouse brain tissue was used in real-time PCR with mtND2 primers targeting mouse mtDNA (n = 4 mice per group). (B) mtND2 DNA content in plasma samples from mouse blood collected at the age of 13 wk were assayed by real-time PCR (n = 10 WT and n = 8 R6/2 Tg mice). Housekeeping nuclear gene, GAPDH, was used for normalization. (C) Change in mtND2 levels over time in mice. Mouse plasma samples from WT and R6/2 mice were collected every 2 wk, and mtND2 levels were determined using real-time PCR. mtND2 levels decreased over time in R6/2 mice as compared with WT mice (n = 10 WT; n = 10 R6/2 [5–11-wk-old mice]; n = 9 [13-wk-old mice]). The data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0006; **, P = 0.0055; ***, P = 0.00017 versus WT 5 wk; #, P = 0.00085 versus WT 7 wk; ##, P = 0.004 versus WT 13 wk (unpaired Student’s t test and one-way ANOVA).CC BY-NC-SA · PubMed Central
Figure 2. Behavioral phenotype of R6/2 mice compared with WT. (A) R6/2 mice have significantly decreased latency to fall during the accelerating rotor rod test (4–40 rpm) starting at 7 wk of age and progressively exhibit a shorter latency as they age. WT mice maintained their latency to falling as they aged. n = 10 WT and n = 9 R6/2. *, P = 0.0001 WT versus R6/2 at respective week; two-way ANOVA, repeated measure with Bonferroni posthoc analysis. (B) 11-wk-old WT mice were able to find the location of the new escape box during the DMP-DM test, and their latency to finding the escape box decreased as more training days were conducted. The latency to find the escape box for 11-wk-old R6/2 mice remained stagnant during the four trials of training per day and across multiple days of testing. n = 10 WT and n = 9 R6/2. *, P = 0.0001 WT versus R6/2 at each trial; two-way ANOVA, repeated measure. Error bars represent mean ± SEM.
Figure 2. Behavioral phenotype of R6/2 mice compared with WT. (A) R6/2 mice have significantly decreased latency to fall during the accelerating rotor rod test (4–40 rpm) starting at 7 wk of age and progressively exhibit a shorter latency as they age. WT mice maintained their latency to falling as they aged. n = 10 WT and n = 9 R6/2. *, P = 0.0001 WT versus R6/2 at respective week; two-way ANOVA, repeated measure with Bonferroni posthoc analysis. (B) 11-wk-old WT mice were able to find the location of the new escape box during the DMP-DM test, and their latency to finding the escape box decreased as more training days were conducted. The latency to find the escape box for 11-wk-old R6/2 mice remained stagnant during the four trials of training per day and across multiple days of testing. n = 10 WT and n = 9 R6/2. *, P = 0.0001 WT versus R6/2 at each trial; two-way ANOVA, repeated measure. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 3. Beneficial effect of P110 treatment on R6/2 mice as measured by normalizing mtND2 levels in plasma. (A) WT and R6/2 mice were treated with TAT or P110 for 8 wk at 3 mg/kg/d. mtND2 levels were analyzed by real-time PCR. n = 9/group WT TAT or P110; n = 8 R6/2 TAT; n = 7 R6/2 P110. *, P = 0.004 versus WT TAT; **, P = 0.0005 versus R6/2 TAT. (B) WT and R6/2 mice were treated intermittently with TAT or P110 for 1 wk followed by 3 wk no treatment before another week of treatment was administered. Mice plasma samples were collected 3 wk after the end of the treatment, at the age of 13 wk. n = 9/group WT TAT and P110; n = 11 R6/2 TAT; n = 15 R6/2 P110. #, P = 0.017 versus WT TAT; ##, P = 0.021 versus R6/2 TAT (unpaired Student’s t test and one-way ANOVA). (A and B) Data are presented as mean ± SEM of 2−ΔΔCT. (C) Survival curve of WT and R6/2 mice treated with P110. The mice were treated with TAT and P110 for 8 wk. 4 mice out of 10 R6/2 TAT-treated mice and 2 mice out of 10 R6/2 P110-treated mice died at the age of 13 wk. The results are shown as a log-rank (Mantel-Cox) test; χ2 = 10.9; P = 0.0123. (D) The effect of intermittent treatment of P110 on WT and R6/2 mice over 8 wk. 4 out of 10 R6/2 mice treated with TAT died whereas 0 out of 10 R6/2 mice treated with P110 died at the age of 13 wk; no death occurred in the 10 TAT- and 10 P110-treated WT mice. The results are shown as a log-rank (Mantel-Cox) test; χ2 = 9.461; P = 0.0238.
Figure 3. Beneficial effect of P110 treatment on R6/2 mice as measured by normalizing mtND2 levels in plasma. (A) WT and R6/2 mice were treated with TAT or P110 for 8 wk at 3 mg/kg/d. mtND2 levels were analyzed by real-time PCR. n = 9/group WT TAT or P110; n = 8 R6/2 TAT; n = 7 R6/2 P110. *, P = 0.004 versus WT TAT; **, P = 0.0005 versus R6/2 TAT. (B) WT and R6/2 mice were treated intermittently with TAT or P110 for 1 wk followed by 3 wk no treatment before another week of treatment was administered. Mice plasma samples were collected 3 wk after the end of the treatment, at the age of 13 wk. n = 9/group WT TAT and P110; n = 11 R6/2 TAT; n = 15 R6/2 P110. #, P = 0.017 versus WT TAT; ##, P = 0.021 versus R6/2 TAT (unpaired Student’s t test and one-way ANOVA). (A and B) Data are presented as mean ± SEM of 2−ΔΔCT. (C) Survival curve of WT and R6/2 mice treated with P110. The mice were treated with TAT and P110 for 8 wk. 4 mice out of 10 R6/2 TAT-treated mice and 2 mice out of 10 R6/2 P110-treated mice died at the age of 13 wk. The results are shown as a log-rank (Mantel-Cox) test; χ2 = 10.9; P = 0.0123. (D) The effect of intermittent treatment of P110 on WT and R6/2 mice over 8 wk. 4 out of 10 R6/2 mice treated with TAT died whereas 0 out of 10 R6/2 mice treated with P110 died at the age of 13 wk; no death occurred in the 10 TAT- and 10 P110-treated WT mice. The results are shown as a log-rank (Mantel-Cox) test; χ2 = 9.461; P = 0.0238.CC BY-NC-SA · PubMed Central
Figure 4. DNA damage measurement in urine and inflammation markers in plasma of WT and R6/2 mice. (A) Analysis of 8-OHdG levels in urine samples of 13-wk-old WT and R6/2 mice that were treated with TAT or P110 for 8 wk. The levels of 8-OHdG were measured by ELISA. Creatinine levels in the same urine samples were determined for normalization. Increased levels of 8-OHdG in the urine of R6/2 mice were normalized to WT levels after P110 treatment. Data are presented as mean ± SEM (n = 9/group WT TAT and P110; n = 6 R6/2 TAT; n = 7 R6/2 P110). (B and C) TNF (B) and IL-6 (C) levels measured by ELISA in mice plasma of respective mice treated with TAT and P110 for 8 wk. Plasma samples were collected at 13 wk of age. TNFα: n = 7/group WT TAT and P110; n = 9 R6/2 TAT; n = 10 R6/2 P110. IL-6: n = 4/group WT TAT and P110; n = 9 R6/2 TAT; n = 10 R6/2 P110. Data are presented as mean ± SEM. *, P = 0.03 R6/2 TAT versus WT TAT; **, P = 0.043 R6/2 P110 versus R6/2 TAT (unpaired Student’s t test); ***, P = 0.0006 R6/2 TAT versus WT TAT; #, P = 0.0023 R6/2 P110 versus R6/2 TAT; ##, P = 0.01 R6/2 TAT versus WT TAT; ###, P = 0.0003 R6/2 P110 versus R6/2 TAT (unpaired Student’s t test and one-way ANOVA).
Figure 4. DNA damage measurement in urine and inflammation markers in plasma of WT and R6/2 mice. (A) Analysis of 8-OHdG levels in urine samples of 13-wk-old WT and R6/2 mice that were treated with TAT or P110 for 8 wk. The levels of 8-OHdG were measured by ELISA. Creatinine levels in the same urine samples were determined for normalization. Increased levels of 8-OHdG in the urine of R6/2 mice were normalized to WT levels after P110 treatment. Data are presented as mean ± SEM (n = 9/group WT TAT and P110; n = 6 R6/2 TAT; n = 7 R6/2 P110). (B and C) TNF (B) and IL-6 (C) levels measured by ELISA in mice plasma of respective mice treated with TAT and P110 for 8 wk. Plasma samples were collected at 13 wk of age. TNFα: n = 7/group WT TAT and P110; n = 9 R6/2 TAT; n = 10 R6/2 P110. IL-6: n = 4/group WT TAT and P110; n = 9 R6/2 TAT; n = 10 R6/2 P110. Data are presented as mean ± SEM. *, P = 0.03 R6/2 TAT versus WT TAT; **, P = 0.043 R6/2 P110 versus R6/2 TAT (unpaired Student’s t test); ***, P = 0.0006 R6/2 TAT versus WT TAT; #, P = 0.0023 R6/2 P110 versus R6/2 TAT; ##, P = 0.01 R6/2 TAT versus WT TAT; ###, P = 0.0003 R6/2 P110 versus R6/2 TAT (unpaired Student’s t test and one-way ANOVA).CC BY-NC-SA · PubMed Central
Figure 5. P110 reduces mtHtt aggregation in R6/2 skeletal muscle. Skeletal muscle sections were stained with anti-mtHtt (EM-48) antibody and hematoxylin (blue nuclei). More aggregates of mtHtt were found (arrows) in TAT-treated than P110-treated R6/2 mice. (Bottom) Magnification of boxed areas.
Figure 5. P110 reduces mtHtt aggregation in R6/2 skeletal muscle. Skeletal muscle sections were stained with anti-mtHtt (EM-48) antibody and hematoxylin (blue nuclei). More aggregates of mtHtt were found (arrows) in TAT-treated than P110-treated R6/2 mice. (Bottom) Magnification of boxed areas.CC BY-NC-SA · PubMed Central
Figure 6. P110 reduces mtHtt aggregation in R6/2 skin. Skin sections were analyzed for the presence of mtHtt in WT and R6/2 mice. P110 reduced the level of mtHtt aggregates. (Bottom) Magnification of boxed areas.
Figure 6. P110 reduces mtHtt aggregation in R6/2 skin. Skin sections were analyzed for the presence of mtHtt in WT and R6/2 mice. P110 reduced the level of mtHtt aggregates. (Bottom) Magnification of boxed areas.CC BY-NC-SA · PubMed Central
Figure 7. mtDNA in HD patients and control subjects. (A) Distribution of mtND2 levels in plasma among the groups of human plasma were analyzed by real-time PCR. The scatter plot illustrates the CT values of GAPDH (x axis) against CT values of mtND2 (y axis) in human plasma of non-HD, premanifest (Pre-man), and HD subjects. CT values of mtND2 of HD plasma were lower and clustered below the 50% line compared with premanifest HD and non-HD groups. (B) mtND2 levels were significantly higher in HD plasma versus non-HD plasma (n = 6/non-HD and HD; n = 5/premanifest). Data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0415 HD versus non-HD (one-way ANOVA).
Figure 7. mtDNA in HD patients and control subjects. (A) Distribution of mtND2 levels in plasma among the groups of human plasma were analyzed by real-time PCR. The scatter plot illustrates the CT values of GAPDH (x axis) against CT values of mtND2 (y axis) in human plasma of non-HD, premanifest (Pre-man), and HD subjects. CT values of mtND2 of HD plasma were lower and clustered below the 50% line compared with premanifest HD and non-HD groups. (B) mtND2 levels were significantly higher in HD plasma versus non-HD plasma (n = 6/non-HD and HD; n = 5/premanifest). Data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0415 HD versus non-HD (one-way ANOVA).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 58

Metadata

Authors
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D.
Affiliations
  • Stanford Medicine (US)
  • University of British Columbia (CA)
  • Case Western Reserve University (US)
  • Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305 1
Venue
Journal of Experimental Medicine
Published
2016-11-07
Volume
213
Issue
12
Pages
2655-2669
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2554473742
Cited by
58
References
69
Citations by year
2026: 3 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 11 · 2017: 2
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HL52141)
  • TAKEDA Pharmaceuticals U.S.A.
  • NIH (R01 NS088192)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Huntington's disease, peripheral biomarkers, disease progression, treatment response, p110, mitochondrial fragmentation, mitochondrial DNA, oxidative DNA damage, 4-hydroxynonenal, mutant huntingtin aggregates, neuroinflammation, R6/2 mice, plasma biomarkers, clinical trial endpoints
MeSH terms
Aldehydes, Animals, Behavior, Animal, Body Fluids, Brain, DNA Damage, DNA, Mitochondrial, Humans, Huntington Disease, Inflammation, Mitochondria, Oxidation-Reduction, Phenotype, Biomarkers, Case-Control Studies, Disease Progression, Muscle, Skeletal, Mice, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential biomarkers to follow the progression and treatment response of Huntington’s disease. https://app.cochat.ai/papers/10.1084/jem.20160776
The paper
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016). Potential biomarkers to follow the progression and treatment response of Huntington’s disease. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20160776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.